Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6

Pharmacogenetics

Volumn 9, Issue 5, 1999, Pages 551-559

  Dilger, Karin ^a   Greiner, Bernd ^b   Fromm, Martin F ^a   Hofmann, Ute ^a   Kroemer, Heyo K ^c   Eichelbaum, Michel ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Drug metabolism; Pharmacogenetics; Propafenone

Indexed keywords

ANTIARRHYTHMIC AGENT; PROPAFENONE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; DEALKYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PRIORITY JOURNAL; QRS COMPLEX;

EID: 0032738791     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199910000-00002     Document Type: Article

References (38)

1. Adedoyin A, Mauro K, Kubisty C, Boyer A, Porter J, Branch RA. Chronic modulation of CYP2D6 and CYP3A4 activities by quinidin and rifampicin, respectively. Clin Pharmacol Ther 1995; 57:210.
2. Batt AM, Magdalou J, Vincent-Viry M, Ouzzine M, Fournel-Gigleux S, Galteau MM, Siest G. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucurono-syltransferases. Clin Chim Acta 1994; 225:171-190.
3. Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol 1987: 31:677-683.
4. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993; 43:120-126.
5. Bryson HM, Palmer KJ, Langtry HD, Fitton A. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45:85-130.
6. Burchell B, Coughtrie WH. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 1997; 105:739-747.
7. Caraco Y, Sheller J, Wood AJJ. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. JPET 1997; 281:330-336.
8. Castel JM, Cappiello E, Leopaldi D, Latini R. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect. Br J Clin Pharmacol 1990; 30:155-156.
9. Chiba P, Ecker G, Schmid D, Drach J, Tell B, Goldenberg S, Gekeler V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 1996; 49:1122-1130.
10. Eichelbaum M, Bertilsson L, Saewe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31;184-186.
11. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986; 22:49-53.
12. Fromm MF, Botsch S, Heinkele G, Evers J, Kroemer HK. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol 1995; 48:279-283.
13. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport. A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99:552-557.
14. Haefeli EW, Vozeh S, Ha HR, Follath F. Comparison of the pharmaco-dynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 1990; 48:245-25.
15. Haefeli EW, Vozeh S, Ha HR, Taeschner W, Follath F. Concentration-effect relations of 5-hydroxypropafenone in normal subjects. Am J Cardiol 1991; 67:1022-1026.
16. 2H-labelled propafenone in man. Eur J Drug Metabol Pharmacokinet 1984; 9:41-55.
17. Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhan OH. Investigations on the pharmacokinetics of propafenone in man. Drug Res 1983; 33:763-770.
18. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987; 42:305-311.
19. Kern A, Bader A, Pihlmayr R, Sewing KF. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 1997; 54:761-777.
20. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90:1871-1878.
21. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989a; 45:28-33.
22. Kroemer HK, Turgeon J, Thomas T, Roden DM. Accumulation of propafenone glucuronide during chronic oral therapy in man [abstract]. Clin Pharmacol Ther 1989b; 45:180.
23. Kroemer HK, Klotz U. Glucuronidation of drugs. A reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992; 23:292-310.
24. Leclercq V, Desager JP, Horsmans Y, Van Nieuwenhuyze Y, Harvengt C. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. Int J Clin Pharmacol Ther Toxicol 1989; 27:593-598.
25. Prescott LF, Critchley JAJH, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol 1981; 12:149-153.
26. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. Baltimore: Williams & Wilkins; 1995.
27. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49:311-318.
28. Seidemann P, Ericsson O, Groningsson K, von Bahr C. Effect of pentobarbital on the formation of diastereomeric oxazepam glucuronides in man: analysis by high performance liquid chromatography. Acta Pharmacol Toxicol (Copenh) 1981; 49:200-204.
29. Siddoway LA, Roden DM, Woosley RL. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol 1984; 54:9D-12D.
30. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75:785-791.
31. Somogyi A, Eichelbaum M, Gugler R. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol 1982; 22:85-90.
32. Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III. Arch Intern Med 1997; 157:2453-2458.
33. Strolin Benedetti M, Duchene P, Olliaro P. Investigation on a possible induction of AZT glucuronidation by rifabutin and rifampicin in humans (abstract). In: Proceedings of the Third International ISSX Meeting, 24-28 June 1991; Amsterdam, pp. 295.
34. Stueven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996; 6:417-421.
35. Tonn GR, Kerr CR, Axelson JE. In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins, and to red blood cells. J Pharm Sci 1992; 81:1098-1103.
36. Vozeh S, Haefeli W, Ha HR, Vlcek J, Follath F. Nonlinear kinetics of propafenone metabolites in healthy man. Eur J Clin Pharmacol 1990; 38:509-513.
37. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. JPET 1997; 283:39-45.
38. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OFW. The effect of age upon liver volume and apparent liver blood flow in healthy men. Hepatology 1989; 9:297-301.